Metrics as of 10/17/2026, 04:34 AM (Berlin time), refresh in progress.
Crinetics Pharmaceuticals Stock
Crinetics Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- R. Scott Struthers
- Employees
- 594
- Market cap
- $9 B
- IPO
- 18/07/2018
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical enterprise based in San Diego, USA. The company is dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. A central component of its portfolio is the…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Crinetics Pharmaceuticals stock: price history
1D
+0.0%
1W
+0.1%
1M
+1.4%
6M
+115.0%
YTD
+82.5%
1Y
+155.1%
2Y
+60.1%
5Y
+244.3%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% stronger price swings than usual
Crinetics Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company specializing in the identification and commercialization of therapeutics for rare endocrine disorders and associated tumors. The business model focuses on highly specialized drug candidates such as paltusotine, which has already advanced through Phase III trials for the treatment of acromegaly. Revenue generation occurs primarily through product sales as well as licensing and services. By concentrating on rare indications, the company benefits from regulatory barriers to entry and highly specialized therapeutic approaches.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Crinetics Pharmaceuticals
Analyst assessment of Crinetics Pharmaceuticals
PRICE TARGET LOW
US$84.00
CONSENSUS
US$84.86
MEDIAN
US$85.00
PRICE TARGET HIGH
US$85.00
0
STRONG BUY
13
BUY
8
HOLD
0
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 28/07/2026
Crinetics Pharmaceuticals stock metrics
P/E
-16.82
P/B
7.52
EV/EBITDA
-17.7
RETURN ON EQUITY
-10.1%
NET MARGIN
-481.1%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.8%
FLOAT SHARES
99,409,534
AVG. DAILY VOLUME (30D)
2,427,330
Insider transactions (SEC)
WIERENGA WENDELL
Struthers Richard Scott
Struthers Richard Scott
Struthers Richard Scott
Struthers Richard Scott
Institutional holders
Comparable stocks
Frequently asked questions about Crinetics Pharmaceuticals stock
What does Crinetics Pharmaceuticals do?
Crinetics Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is R. Scott Struthers, the company employs around 594 people.
The IPO was on 18/07/2018; the stock trades on NASDAQ under the ticker CRNX.
What do analysts say about Crinetics Pharmaceuticals stock?
21 analysts rate the stock, the consensus is Buy (as of 28/07/2026).
The average price target is US$84.86, ranging from US$84.00 to US$85.00, with a median of US$85.00.
This is an external assessment, not a statement by Market Jury.
When does Crinetics Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Crinetics Pharmaceuticals pay a dividend?
No, Crinetics Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Crinetics Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Crinetics Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Crinetics Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.